This email notification is intended as a heads up to OHSU communicators. It is not shared with external subscribers.
|
Targeted therapy stops a rare, joint-destroying tumorOHSU cancer researcher helped lead study finding first effective drug therapy for tenosynovial giant cell tumor, or TGCT.
|
|
This email was sent to you by Oregon Health & Science University 3181 S.W. Sam Jackson Park Rd. | Portland, Oregon 97239-3098 |